Stockscreener 앱 받기
10.64
0.65%
-0.07
시간 외 거래:
10.64
전일 마감가:
$10.71
열려 있는:
$10.65
하루 거래량:
1.38M
Relative Volume:
2.62
시가총액:
$449.00M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-2.2735
EPS:
-4.68
순현금흐름:
$-76.57M
1주 성능:
-6.26%
1개월 성능:
-7.07%
6개월 성능:
-31.22%
1년 성능:
-28.45%
1일 변동 폭
$10.51
$11.08
1주일 범위
$10.51
$11.67
52주 변동 폭
$10.51
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
URGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.64 | 449.00M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
URGN stock touches 52-week low at $10.6 amid market challenges - Investing.com Canada
URGN stock touches 52-week low at $10.6 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70 - MarketBeat
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
(URGN) Investment Report - Stock Traders Daily
UroGen Pharma Grants 112,800 RSUs to Expand Commercial Team for Jelmyto Rollout - StockTitan
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
URGN (UroGen Pharma) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma Ltd. (NASDAQ:URGN) Holdings Raised by RTW Investments LP - MarketBeat
UroGen's Bladder Cancer Drug Shows Breakthrough 82% Response Rate in Phase 3 Trial - StockTitan
Parkman Healthcare Partners LLC Has $4.41 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade - Yahoo Finance
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - BioSpace
UroGen Pharma Unveils Key Clinical Data for Cancer Treatment Pipeline at SUO 2024 - StockTitan
URGN (UroGen Pharma) Shares Outstanding (EOP) : 42.19 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Shares Outstanding (EOP) : 36.13 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) PE Ratio without NRI : At Loss (As of Dec. 01, 2024) - GuruFocus.com
Vestal Point Capital LP Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment - Clinical Trials Arena
Financial Review: UroGen Pharma (NASDAQ:URGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World
Great Point Partners LLC Has $9.64 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
JELMYTO shows long-term efficacy in UTUC study - Investing.com India
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire
URGN (UroGen Pharma) GF Value Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Momentum Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St
RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com
Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com
Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com
RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World
UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks
HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Urogen Pharma Ltd 주식 (URGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
2.88%
2.65%
자본화:
|
볼륨(24시간):